Breaking Two Arrested in Connection with Shooting Outside U.S. Consulate Explosion in Syrian Suburb Kills One, Wounds Several Trump Administration Buys Back Offshore Wind Leases for $1.2 Billion Veronica Burton Emerges as Key Player for Second-Year Golden State Valkyries Jalapeño Peppers Linked to Multistate Salmonella Outbreak Traced to Mexican Grower and Distributor

Thursday August 6, 2026

Reporter

NanoViricides

6Articles Published

5Communities Covered

Published Articles

Press Release

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

Jul 6

Press Release

US FDA Has Granted A “Rare Pediatric Disease Drug” Designation for NV-387 As A Treatment for Measles – Enables Priority Review Voucher

Jun 29

Press Release

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

Jun 22

Press Release

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola – NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

Jun 15

Press Release

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies

Jun 8

Press Release

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies

Jun 8